Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyEric Van Cutsem, David Cunningham, J.-L. Canon et al.|Annals of Oncology|2009Cited by 534
Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.TrialScott Berry, Eric VanCutsem, David Cunningham et al.|Journal of Clinical Oncology|2006Cited by 44
Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrialAlbrecht Kretzschmar, David Cunningham, Beatrix Lutiger et al.|Journal of Clinical Oncology|2007Cited by 19